Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study

Table 3 Recommended and observed time between infusions for intravenous biologics

	First-line infliximab^a (n = 506)	Subsequent-line infliximab^a (n = 136)	Abatacept^a (n = 344)	Rituximab^b (n = 139)
Label interval	8 weeks	8 weeks	4 weeks	6 months
Observed interval; mean (SD)	7.82 (2.19) weeks	7.39 (2.09) weeks	4.75 (1.42) weeks	6.8 (2.6) months

^aInterval between doses starting with dose 3, among patients with at least 4 infusions in the follow-up period.
^bInterval defined as the number of days between dose 1 of first course and dose 1 of subsequent course.

ISSN: 1471-2474